JAGX Fundamental Analysis - JAGUAR HEALTH INC

Name: JAGUAR HEALTH INC (JAGX) Stock
Brand: JAGUAR HEALTH INC
Rating: 3.5 (3 reviews)

Fundamental Rating

JAGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. JAGX has a bad profitability rating. Also its financial health evaluation is rather negative. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year JAGX has reported negative net income.

JAGX had a negative operating cash flow in the past year.

JAGX had negative earnings in each of the past 5 years.

In the past 5 years JAGX always reported negative operating cash flow.

1.2 Ratios

JAGX has a worse Return On Assets (-84.21%) than 73.96% of its industry peers.

JAGX's Return On Equity of -508.83% is on the low side compared to the rest of the industry. JAGX is outperformed by 79.69% of its industry peers.

		Industry Rank	Sector Rank
ROA	-84.21%
ROE	-508.83%
ROIC	N/A

ROA(3y)-84.47%

ROA(5y)-88.47%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

JAGX's Gross Margin of 81.88% is amongst the best of the industry. JAGX outperforms 84.90% of its industry peers.

In the last couple of years the Gross Margin of JAGX has grown nicely.

The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	81.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y21.72%

GM growth 5Y19.68%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, JAGX has less shares outstanding

JAGX has less shares outstanding than it did 5 years ago.

JAGX has a better debt/assets ratio than last year.

2.2 Solvency

JAGX has an Altman-Z score of -12.60. This is a bad value and indicates that JAGX is not financially healthy and even has some risk of bankruptcy.

JAGX has a worse Altman-Z score (-12.60) than 76.56% of its industry peers.

JAGX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of JAGX (1.34) is worse than 77.08% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF	N/A
Altman-Z	-12.6

ROIC/WACCN/A

WACC2.24%

2.3 Liquidity

A Current Ratio of 0.95 indicates that JAGX may have some problems paying its short term obligations.

With a Current ratio value of 0.95, JAGX is not doing good in the industry: 84.90% of the companies in the same industry are doing better.

A Quick Ratio of 0.59 indicates that JAGX may have some problems paying its short term obligations.

JAGX has a worse Quick ratio (0.59) than 89.06% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.95
Quick Ratio	0.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

JAGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -79.22%.

Looking at the last year, JAGX shows a quite strong growth in Revenue. The Revenue has grown by 15.95% in the last year.

Measured over the past years, JAGX shows a quite strong growth in Revenue. The Revenue has been growing by 15.14% on average per year.

EPS 1Y (TTM)-79.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.84%

Revenue 1Y (TTM)15.95%

Revenue growth 3Y39.19%

Revenue growth 5Y15.14%

Sales Q2Q%7.9%

3.2 Future

JAGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.54% yearly.

The Revenue is expected to grow by 118.46% on average over the next years. This is a very strong growth

EPS Next Y89.56%

EPS Next 2Y40.54%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year24.03%

Revenue Next 2Y26.98%

Revenue Next 3Y160.53%

Revenue Next 5Y118.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.

Also next year JAGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as JAGX's earnings are expected to grow with 40.54% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.54%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

JAGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

JAGUAR HEALTH INC

NASDAQ:JAGX (11/19/2025, 9:30:35 AM)

1.6

-0.06 (-3.61%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-14 2025-11-14/bmo

Earnings (Next)03-30 2026-03-30/amc

Inst Owners0.7%

Inst Owner Change596.43%

Ins Owners0.06%

Ins Owner Change0%

Market Cap5.63M

Revenue(TTM)11.81M

Net Income(TTM)-40.65M

Analysts85.71

Price Target16.32 (920%)

Short Float %1.47%

Short Ratio0.3

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-16.02%

Min EPS beat(2)-41.08%

Max EPS beat(2)9.04%

EPS beat(4)3

Avg EPS beat(4)30.68%

Min EPS beat(4)-41.08%

Max EPS beat(4)98.2%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-17.44%

Min Revenue beat(2)-23.04%

Max Revenue beat(2)-11.83%

Revenue beat(4)1

Avg Revenue beat(4)-12.25%

Min Revenue beat(4)-23.04%

Max Revenue beat(4)8.52%

Revenue beat(8)2

Avg Revenue beat(8)-11.83%

Revenue beat(12)4

Avg Revenue beat(12)-6.94%

Revenue beat(16)5

Avg Revenue beat(16)-11.51%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.48
P/FCF	N/A
P/OCF	N/A
P/B	0.71
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-53.55

EYN/A

EPS(NY)-5.79

Fwd EYN/A

FCF(TTM)-7.92

FCFYN/A

OCF(TTM)-7.86

OCFYN/A

SpS3.36

BVpS2.27

TBVpS-2.72

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-84.21%
ROE	-508.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	81.88%
FCFM	N/A

ROA(3y)-84.47%

ROA(5y)-88.47%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y21.72%

GM growth 5Y19.68%

F-Score4

Asset Turnover0.24

Health

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.95
Quick Ratio	0.59
Altman-Z	-12.6

F-Score4

WACC2.24%

ROIC/WACCN/A

Cap/Depr(3y)32.24%

Cap/Depr(5y)19.49%

Cap/Sales(3y)5.33%

Cap/Sales(5y)3.24%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-79.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%89.84%

EPS Next Y89.56%

EPS Next 2Y40.54%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)15.95%

Revenue growth 3Y39.19%

Revenue growth 5Y15.14%

Sales Q2Q%7.9%

Revenue Next Year24.03%

Revenue Next 2Y26.98%

Revenue Next 3Y160.53%

Revenue Next 5Y118.46%

EBIT growth 1Y-4.66%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y18.85%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y18.49%

OCF growth 3YN/A

OCF growth 5YN/A

JAGUAR HEALTH INC / JAGX FAQ

What is the fundamental rating for JAGX stock?

ChartMill assigns a fundamental rating of 2 / 10 to JAGX.

Can you provide the valuation status for JAGUAR HEALTH INC?

ChartMill assigns a valuation rating of 1 / 10 to JAGUAR HEALTH INC (JAGX). This can be considered as Overvalued.

What is the profitability of JAGX stock?

JAGUAR HEALTH INC (JAGX) has a profitability rating of 1 / 10.

Can you provide the financial health for JAGX stock?

The financial health rating of JAGUAR HEALTH INC (JAGX) is 1 / 10.

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

JAGUAR HEALTH INC / JAGX FAQ

What is the fundamental rating for JAGX stock?

Can you provide the valuation status for JAGUAR HEALTH INC?

What is the profitability of JAGX stock?

Can you provide the financial health for JAGX stock?